Somatostatin Inhibits Deoxyribonucleic Acid Synthesis Induced by Both Thyrotropin and Insulin-Like Growth Factor-I in FRTL5 Cells*
- 1 June 1990
- journal article
- research article
- Published by The Endocrine Society in Endocrinology
- Vol. 126 (6) , 3131-3138
- https://doi.org/10.1210/endo-126-6-3131
Abstract
Somatostatin, a cyclic tetradecapeptide, is both a hypothalamic hormone and a paracrine peptide, with effects on many tissues. Despite the fact that somatostatin can inhibit various cellular events in a number of cell lines, somatostatin is a constituent of medium defined for optimal growth of FRTL5, a line differentiated and nontransformed rat thyroid follicular cells. In the present study we have evaluated the role of somatostatin in the control of DNA synthesis in FRTL5 cells and have investigated the mechanisms of somatostatin interaction with pathways stimulated by TSH and insulin-like growth factor-I (IGF-I). Somatostatin inhibits TSH-stimulated DNA synthesis and cell proliferation in FRTL5 cells. Maximal effects are observed at somatostatin concentrations of 0.1-10 ng/ml, and the effects are diminished at somatostatin concentrations above 10 ng/ml. Somatostatin also inhibits (Bu)2cAMP-stimulated DNA synthesis, suggesting that the loci of somatostatin action are both proximal and distal to activation of adenylate cyclase. Somatostatin also inhibits DNA synthesis stimulated by insulin-like growth factor-I (IGF-I), a pleiotropic growth factor that works through non-cAMP-dependent pathways. The somatostatin analog octreotide is more potent than native somatostatin in inhibiting DNA synthesis stimulated by either TSH or IGF-I. Somatostatin does not alter TSH or IGF-I binding to FRTL5, demonstrating that somatostatin affects the postreceptor signal transduction pathways stimulated by these factors. We conclude that 1) the use of somatostatin in hormone-supplemented medium for FRTL5 is unnecessary and may inhibit cell growth; 2) somatostatin can inhibit the direct effects of IGF-I on peripheral tissues in addition to its ability to interfere with IGF-I synthesis by inhibiting the synthesis and release of pituitary GH; and 3) somatostatin is a useful tool for dissecting the pathways involved in mediating differentiated function and growth of FRTL5 cells.This publication has 16 references indexed in Scilit:
- Antiproliferative effects of somatostatin and the somatostatin analog SMS 201-995 on three human breast cancer cell linesZeitschrift für Krebsforschung und Klinische Onkologie, 1988
- Characterization of the cyclic AMP-independent actions of somatostatin in GH cells. I. An increase in potassium conductance is responsible for both the hyperpolarization and the decrease in intracellular free calcium produced by somatostatin.Journal of Biological Chemistry, 1988
- Adenosine 3′,5′-Monophosphate Mediates Both the Mitogenic Effect of Thyrotropin and Its Ability to Amplify the Response to Insulin-Like Growth Factor I in FRTL5 Cells*Endocrinology, 1988
- Insulinlike growth factor I regulation of growth hormone gene transcription in primary rat pituitary cells.Journal of Clinical Investigation, 1987
- INSULIN-LIKE GROWTH FACTOR-I STIMULATES THE GROWTH OF RAT THYROID CELLS IN CULTURE AND SYNERGIZES THE STIMULATION OF DNA SYNTHESIS INDUCED BY TSH AND GRAVES′-IgGEndocrinology, 1986
- Properties and Regulation of the Thyrotropin Receptor in the FRTL5 Rat Thyroid Cell Line*Endocrinology, 1986
- Thyrotropin and dibutyryl cyclic AMP increase levels of c-myc and c-fos mRNAs in cultured rat thyroid cells.Journal of Biological Chemistry, 1986
- Mode of action of somatostatin to inhibit secretion by shark rectal glandAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 1985
- Association of the changes in cytosolic Ca2+ and iodide efflux induced by thyrotropin and by the stimulation of alpha 1-adrenergic receptors in cultured rat thyroid cells.Journal of Biological Chemistry, 1985
- Somatostatin Inhibits Vasoactive Intestinal Peptide-Stimulated Cyclic Adenosine Monophosphate Accumulation in GH Pituitary Cells*Endocrinology, 1983